Meeting Minutes

Date: Wednesday, July 20, 2022
Time: 10:00 AM – 12:00 PM
Location: Zoom and Magnuson Health Sciences Building T-269

Members Present:
1. Jim Boonyaratanakornkit, Allergy and Infectious Diseases
2. Lesley Colby, Comparative Medicine (Animal Containment Expert)
3. Lesley Decker, Environmental Health & Safety (Biosafety Officer)
4. David Koelle, Allergy and Infectious Diseases
5. Stephen Libby, Laboratory Medicine
6. Susan Parazzoli (Community Member)
7. Jason Smith, Microbiology (IBC Chair)
8. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)

Commonly Used Abbreviations
IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BUA: Biological Use Authorization
BSL: biosafety level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
DURC: Dual Use Research of Concern
SOP: standard operating procedure
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the June 15, 2022, meeting.
   - A member made a motion to approve the June 15, 2022, minutes. Another member seconded the motion.
   - The committee voted to approve the June 15, 2022, meeting minutes, with three members abstaining.

4. **OLD BUSINESS:**
   - At the June 15, 2022, meeting, Dr. Gale’s BUA was approved pending an occupational health review. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Geisse’s BUA was approved pending a successful lab inspection completion. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Miller’s BUA was approved pending a successful lab inspection completion. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Oshima’s BUA was approved pending a successful lab inspection completion and clarification of use of oncogenes with viral vectors. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Villen’s BUA was approved pending a successful lab inspection completion. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. von Moltke’s BUA was approved pending a successful lab inspection completion, IACUC protocol revisions, and confirmation of the BSL for Trichuris muris in mice. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Walker’s BUA was approved pending a successful lab inspection completion. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Young’s BUA was approved pending a successful lab inspection completion. This BUA has been sent out by the BSO.
   - At the June 15, 2022, meeting, Dr. Gale’s BUA was approved pending a medical management plan for Japanese encephalitis virus. This BUA has been sent out by the BSO.

5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the NIH Guidelines, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.

   a. Biosafety Officer Report
      - Dr. Henning added new rooms for work with previously approved agents to the BUA Sepsis and AKI.
      - Dr. Liu renewed the BUA Microscopy of human tissue specimens with human blood, tissue, body fluids, and cells lines.
      - Dr. Nemhauser added new space in the UW Botany Greenhouse for work with previously approved agents to the BUA Manipulation and Dissection of Growth Control Networks.
• Dr. McLean renewed work with wildtype Risk Group 1 and 2 microorganisms on the BUA Domestication and characterization of TM7.
• Dr. Hoofnagle renewed work with human blood, tissue, body fluids, and cell lines on the BUA Analysis of human samples for the development of novel diagnostic assays in the clinical laboratory and for the investigation into nutrition, obesity, kidney disease, cardiovascular disease, and neurodegenerative diseases.
• Dr. Wood was approved for work with Mycoplasma genitalium in mice on the BUA Mouse model of Mycoplasma genitalium infection.
• Dr. Imoukhuede was approved for work with human blood, tissue, body fluids, and cell lines on the new BUA Quantifying receptor protein expression and signaling in human and mouse cells.
• Dr. Bermingham-McDonogh renewed the BUA Sensory cell development and regeneration in the inner ear working with recDNA in vitro.
• Dr. Chu renewed the BUA Seattle Flu Study working with human and non-human primate samples and Risk Group 2 microorganisms.
• Dr. Tait Wojno renewed the BUA Regulation of immunity and inflammation at mucosal surfaces working with Risk Group 1 helminths in vitro and in vivo in mice and rats.
• Dr. Raible added new spaces for work with previously approved agents to the BUA Regulation of Zebrafish Development.
• Dr. Lin renewed the BUA Epigenomics of Heart Failure. Work includes use of human cell lines and recombinant DNA.
• Dr. Corey added new rooms to the BUA Pre-Clinical Models, Mechanisms, and Markers of Prostate Cancer and Prostate Cancer Metastasis.
• Dr. Carlson renewed the BUA Synaptic Laminin and the Calcium Channel for work with human cells and recDNA.
• Dr. Veesler added new rooms for work with previously approved agents in the BUA Expression of recombinant proteins using mammalian cell lines.
• Dr. Klavins received approval for work with recDNA on the BUA Yeast display assay for synthetic protein screening.
• Dr. Muller added use of new core facilities and equipment for use with previously approved agents to the BUA Andrology Research Lab/Male Fertility Clinic.
• Dr. Hyde merged two BUAs and updated the title: Pathogenesis studies of alphaviruses and +ssRNA viruses.
• Dr. Fuller added non-human primate tissue co-infected with SIV and SARS-CoV-2 for use in the BSL-3 Facility to the BUA DNA Vaccine Therapy.
• Dr. Duthie added the Zostavax vaccine in mice to the BUA Novel immunization strategies to protect against infectious diseases.
• Dr. Simpson received approval for a limited duration study involving human blood for the BUA Do terpenes play a role in the stress reducing effect of a forest bathing intervention?
• Dr. Barria added use of the Keck Microscopy Facility to the BUA Regulation of Glutamatergic Synapses.
• Dr. Hall took over as the PI for the BUA An Open-Label, Multicenter, Phase ½ Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors.
• Dr. Smith added non-recombinant enteroviruses (excluding poliovirus) and human rhinoviruses A, B, C to the BUA Antiviral Mechanisms of Defensins.
• Dr. Erasmus added non-recombinant enterovirus D in mice to the BUA RNA vaccines.
• Dr. Subramanian renewed work with Risk Group 2 microorganisms and human cells in mice on the BUA A systems approach to understanding NLR function.
• Dr. Froehner received approval for a new BUA Froehner DOD for work with previously approved agents in mouse models.
• The IBC Chair made a motion to approve this month’s Biosafety Officer Report.
• A member made a motion to approve this month’s Biosafety Officer Report. Another member seconded the motion.
• The Committee voted to approve this month’s Biosafety Officer Report with one abstention.

6. BSL-3 INACTIVATION REPORT
• No BSL-3 inactivation report was presented at this meeting.
• An inactivation failure occurred in n-dodecyl-beta-maltoside detergent (DDM) treated SAR-CoV-2 samples. Inactivated samples were not removed from the BSL-3 facility. The cause of the failure was identified as a need for an increased incubation time and potentially a need for a heat treatment step. The lab has modified their SOP to address these causes and is re-validating the samples using the modified SOP. These validation results will be sent to EH&S for review prior to removing the samples from the facility.

7. INDIVIDUAL PROJECT REVIEWS

a. Bair, Wyeth, renewal, Functional Circuitry in the macaque visual system
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Bair lab studies how neurons in the visual cortex process and represent information about the visual world. They aim to develop methods to record signals from many neurons simultaneously.
• The lab administers adeno-associated viral vectors to non-human primates.
• A lab inspection was not required as all work takes place inside a vivarium.
• All required trainings are complete.
• This project has an IACUC protocol in review.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Bair.
• The Committee voted unanimously to approve the draft BUA for Dr. Bair.

b. Bornfeldt, Karin, renewal, Cardiovascular Disease and Diabetes
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Bornfeldt lab identifies the mechanisms whereby diabetes promotes cardiovascular disease. Their goal is to find the culprits responsible for the increased cardiovascular disease associated with diabetes so that new treatment and prevention strategies can be developed.
• The lab works with lymphocytic choriomeningitis virus (LCMV), ecotropic gammaretroviral vectors, and human blood, tissues, and cells
• The lab was inspected, and all deficiencies have been corrected.
• All required trainings are complete.
• This project has an IACUC protocol in review.
• The draft BUA letter was shown.
The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Bornfeldt.

The Committee voted unanimously to approve the draft BUA for Dr. Bornfeldt.

c. Chen, Eleanor, renewal, *Druggable Pathways in Rhabdomyosarcoma*

The assigned IBC Primary Reviewer presented the Primary Review.

This lab uses zebrafish, mice and human cells as tools to study rhabdomyosarcoma, a common pediatric cancer, and to identify novel molecular pathways that are important to drive tumor formation. The long-term goal is to identify drug targets to improve survival of patients with rhabdomyosarcoma.

Work includes transgenic zebrafish and lentiviral vectors in human cells.

The lab was inspected, and all deficiencies have been corrected.

All required trainings are complete.

This project has an IACUC protocol in review.

The draft BUA letter was shown.

The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chen.

The Committee voted unanimously to approve the draft BUA for Dr. Chen.

d. Dhaka, Ajay, renewal, *Dhaka Zebrafish*

The assigned IBC Primary Reviewer presented the Primary Review.

The Dhaka lab works to understand how neural crest cells and cranial placode progenitors generate different cell types including the neurons of the peripheral nervous system. They use zebrafish to understand the genetic and neural basis of nociception.

The lab uses strains of E. coli to engineer plasmids with various fluorescent reporter genes to create and breed transgenic zebrafish.

The lab was inspected, and all deficiencies have been corrected.

The required trainings are still pending.

The IACUC protocol is still pending.

The draft BUA letter was shown.

The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Dhaka.

The Committee voted unanimously to approve the draft BUA for Dr. Dhaka.

e. Duthie, Malcom, new, *Immune modulators for treatment of infection*

The assigned IBC Primary Reviewer presented the Primary Review.

The Duthie lab is doing research to develop innate immune agonists as broad-spectrum antivirals to be delivered as an intranasal spray as a pre-exposure or post-exposure prophylaxis or therapeutic against viral respiratory pathogens.

This project includes exposing mice to influenza viruses, respiratory syncytial virus and mRNA vaccines.

There was a discussion about influenza strains that are regulated by the select agent program. If such strains have modified so as to no longer be a select agent, the BUA application needs to fully describe this.

A lab inspection was not required as all work takes place inside a vivarium.

All required trainings are complete.

This project has an IACUC protocol in review.

The draft BUA letter was shown.

The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Duthie.
f. Elkon, Keith, renewal, *Genetic, Cellular, and Molecular Studies in SLE (Apoptosis)*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Keith lab studies the cGAS-STING response in autoimmune disease in humans and the inflammatory UV response in mice.
   - This research includes working with human blood, tissues, and human cancer cell lines.
   - A lab inspection has been performed and is still pending a response.
   - All required trainings are complete.
   - This project has an IACUC protocol in review.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Elkon.
   - The Committee voted unanimously to approve the draft BUA for Dr. Elkon pending successful completion of the lab inspection.

g. Giachelli, Cecilia, change, *Inflammation and Ectopic Calcification*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Giachelli lab is adding iPS cell lines made with lentiviral and Sendai viral vectors.
   - A discussion regarding if iPS cells generated with a Sendai viral vector are passaged enough times, they may no longer have the viral vector present and would no longer be covered by the NIH Guidelines. However, labs would need to test for the presence of virus.
   - A lab inspection was not required, as the lab was recently inspected.
   - All required trainings are complete.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Giachelli.
   - The Committee voted unanimously to approve the draft BUA for Dr. Giachelli pending their written BSL-2 with BSL-3 practices SOP.

h. Hu, Shiu-Lok, renewal, *Glycan modification, CD4 independence, and Env Immunogenicity*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Hu lab aims to examine novel concepts in vaccine design and immunization methods for HIV/AIDS. Information obtained may provide a rational basis for the development of effective vaccines against HIV/AIDS.
   - The lab works with recombinant vaccinia virus, SHIV and nonhuman primates.
   - A lab inspection was not required as the lab was recently inspected.
   - All required trainings are complete.
   - This project has an IACUC protocol in review.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hu.
   - The Committee voted unanimously to approve the draft BUA for Dr. Hu.

i. Hybiske, Kevin, renewal, *Chlamydia pathogenesis and immune evasion*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Hybiske lab investigates host-pathogen interactions and pathogenesis strategies of chlamydial pathogens with their respective hosts, using recombinant human cell
culture lines, infected with either wildtype or recombinant Chlamydia species and strains (RG2).

- The lab works with RG2 Chlamydia: C. trachomatis, C. psittaci, C. pneumoniae
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hybiske.
- The Committee voted to approve the draft BUA for Dr. Hybiske with one member not submitting a vote.

**j. Kueh, Hao Yuan, renewal, Single-cell analysis of immune cell fate decisions**

- The assigned IBC Primary Reviewer presented the Primary Review.
- The Kueh lab seeks to understand how cells of the immune system make fate choices, either to turn into types of effector cells, or to respond effectively to pathogens and other challenges. This work will allow them to engineer immune cells to fight cancer and other life-threatening diseases.
- Work includes using third generation lentiviral and ecotropic gammaretroviral vectors. They also use Listeria monocytogenes, Lymphocytic choriomeningitis virus (LCMV) and gammaretroviral vectors with oncogenic inserts in mice.
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- This project has an IACUC protocol in review.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kueh.
- The Committee voted unanimously to approve the draft BUA for Dr. Kueh.

**k. Mack, David, renewal, XR1 gene therapy in DMD rat models**

- The assigned IBC Primary Reviewer presented the Primary Review.
- The overarching goal of the Mack lab is to use gene therapy appropriately to treat disease progression of Duchenne Muscular Dystrophy (DMD). We aim to rescue DMD models by overexpression of FXR1.
- This work involves injection of AAV into rats.
- The lab inspection is scheduled after the IBC meeting.
- All required trainings are complete.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Mack.
- The Committee voted unanimously to approve the draft BUA for Dr. Mack pending the lab inspection.

**l. Neitz (002), Maureen, renewal, Gene therapy and retinal circuits**

- The assigned IBC Primary Reviewer presented the Primary Review.
- The Neitz lab aims to develop effective therapeutic agents for treating blindness in humans and to characterize the retinal circuits for vision in the non-human primate retina.
- The lab performs intraocular injections of AAV (including replication competent AAV libraries) to nonhuman primates. Additionally, they perform intraocular AAV injections on transgenic mice.
• The lab was inspected, and no deficiencies were noted.
• All required trainings are complete.
• This project has an IACUC protocol in review.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Neitz.
• The Committee voted unanimously to approve the draft BUA for Dr. Neitz.

m. Neitz (006), Maureen, renewal, Regeneron M opsin knockout
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Neitz lab goals for this project is to develop adeno-associated virus (AAV)-mediated gene therapy vectors.
• This work includes intraocular injections of recombinant AAV into transgenic mice.
• The lab was inspected, and no deficiencies were noted.
• All required trainings are complete.
• This project has an IACUC protocol in review.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Neitz.
• The Committee voted unanimously to approve the draft BUA for Dr. Neitz.

n. Ojo, Kayode, new, Development of target-based inhibitors of Giardia intestinalis/Giardia lamblia, Trichomonas vaginalis as new treatment options
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Ojo lab aims to validate drug targets in: Giardia intestinalis, or Giardia lamblia, species that causes human and veterinary giardiasis and Trichomonas vaginalis (agent of trichomoniasis).
• There was a discussion about aerosolization during sonication. It was recommended that sonication take place inside a BSC while working on ice.
• The lab was inspected, and no deficiencies were noted.
• All required trainings are complete.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ojo.
• The Committee voted unanimously to approve the draft BUA for Dr. Ojo pending clarification of aerosolization risk.

o. Phillips, Paul, renewal, Phasic Dopamine Release during Motivated Behavior in Rats
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Phillips lab aims to elucidate the basics of brain function during behavior and how alterations in gene function can result in neurological and psychiatric disorders, such as substance abuse disorder.
• This work includes injection of adeno-associated viral vector, canine adeno virus, CRISPR/Cas9.
• The lab inspection will be scheduled for after the IBC meeting.
• All required trainings are complete.
• This project has an IACUC protocol in review.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Phillips.
• The Committee voted unanimously to approve the draft BUA for Dr. Phillips pending successful completion of the lab inspection.
p. Poolos, Nicholas, renewal, Epilepsy and Dendritic Excitability
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Poolos lab investigates potential links between altered activities in either tau protein or a specific mitogen-activated protein kinase (JNK2) and the dysfunctions occurring within the ion channels after acquired insults to the brain. They also study if modifications to the tau proteins can serve as a molecular biomarker of epileptic brain tissue.
   - This work includes the processing and handling of resected human brain tissue.
   - A lab inspection has been performed and is still pending a response.
   - The required trainings are still pending.
   - The IACUC Protocol is still pending.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Poolos.
   - The Committee voted unanimously to approve the draft BUA for Dr. Poolos pending lab inspection response and training.

q. Raible, David, renewal, Regulation of Zebrafish Development
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Raible lab uses zebrafish to understand how mechanosensory hair cells develop, respond to damage and regenerate.
   - This lab creates transgenic zebrafish and works with bungarotoxin, and mitochondrial inhibitors. Additionally, they culture human cell lines and engineer plasmids in laboratory strain E. coli.
   - The lab was inspected, and all deficiencies have been corrected.
   - All required trainings are complete.
   - This project has an IACUC protocol in review.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Raible.
   - The Committee voted unanimously to approve the draft BUA for Dr. Raible.

r. Riffell, Jeffrey, new, Mosquito olfaction
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The Riffell lab examines the olfactory basis of mosquito attraction to important odors, such as those emitted from hosts or nectar sources.
   - This lab works with Aedes aegypti mosquitoes.
   - A discussion occurred regarding the appropriate biosafety level for transgenic mosquitoes. Although the proposed modifications are not inherently hazardous, ACL-2 containment is appropriate to prevent release of transgenic mosquitoes.
   - A lab inspection has been performed and is still pending a response.
   - All required trainings are complete.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Riffell.
   - The Committee voted unanimously to approve the draft BUA for Dr. Riffell pending successful completion of the lab inspection.

s. Ruohola-Baker, Hannele, renewal, microRNA Function in Human Embryonic Stem Cells
   - The assigned IBC Primary Reviewer presented the Primary Review.
• The Ruohola-Baker lab aims to understand the key microRNAs in human embryonic stem cells and what their functions are. Additionally, they study the role of polycomb repressive complex 2 in epigenetic regulation in development and cancer.
• This lab works with human embryonic stem cells and human induced pluripotent stem cells generated with Sendai viral vectors with oncogenes.
• The lab inspection will be scheduled for after the IBC meeting.
• All required trainings are complete.
• The IACUC Protocol is still pending.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ruohola-Baker.
• The Committee voted unanimously to approve the draft BUA for Dr. Ruohola-Baker pending successful completion of the lab inspection and review of the IACUC protocol.

t. Valdmanis, Paul, change, Mitigating host responses for effective gene therapy
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Valdmanis lab is adding antisense oligonucleotides (ASOs) as a delivery agent in vivo in mice and two new gene inserts for in vivo and in vitro work.
• A lab inspection is not required for this change.
• All required trainings are complete.
• The draft BUA letter was shown.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Valdmanis.
• The Committee voted unanimously to approve the draft BUA for Dr. Valdmanis.

u. Yang, Kai-Chun (Daniel), new, Modeling genetic cardiomyopathies with hiPSCs
• The assigned IBC Primary Reviewer presented the Primary Review.
• The Yang lab aims to understand the molecular basis of hypertrophic, dilated, and arrhythmogenic cardiomyopathies.
• The work in this lab involves handling of human induced pluripotent stem cells generated with Sendai viral vectors with oncogenes.
• A lab inspection has been performed and is still pending a response.
• All required trainings are complete.
• The draft BUA letter was shown.
• A member made a motion to approve the draft BUA letter for Dr. Yang. Another member seconded the motion.
• The Committee voted unanimously to approve the draft BUA for Dr. Yang pending the lab inspection response.

8. SUBCOMMITTEE REPORTS:

v. Hawn, Thomas, renewal, Innate Immunity and Susceptibility to Infectious Disease
• Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
• The Hawn lab investigates molecular, cellular, and immunologic mechanisms of disease pathogenesis with an emphasis on genetic studies of the innate immune response.
• This work involves BSL-3 work with Mycobacterium tuberculosis.
There was a discussion about the risk group for *Mycobacterium smegmatis*. BSL-2 was determined to be the appropriate safety level.

A lab inspection has been performed and is still pending a response.

All required trainings are complete.

The draft BUA letter was shown.

A member made a motion to approve the draft BUA letter for Dr. Hawn. Another member seconded the motion.

The Committee voted unanimously to approve the draft BUA for Dr. Hawn pending completion of required training.

---

w. Jerome, Keith, change, *Understanding viral antibody resistance*

Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.

The Jerome lab is adding non-human coronaviruses, Vaccinia virus, filovirus nucleocapsid gene blocks, and purified whole genome or synthetic partial genome monkeypox DNA.

A lab inspection has been performed and is still pending a response.

The required trainings are still pending.

An occupational review of non-human coronaviruses is still pending.

The draft BUA letter was shown.

A member made a motion to approve the draft BUA letter for Dr. Jerome. Another member seconded the motion.

The Committee voted unanimously to approve the draft BUA for Dr. Jerome pending the occupational health review and lab inspection responses.

---

x. Koelle, David, change, *Koelle Laboratory at UW*

Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.

The Koelle lab is adding human blood or tissue samples suspected of monkeypox infection.

A lab inspection has been performed and is still pending a response.

All required trainings are complete.

An occupational health review for use of clinical samples from monkeypox patients is still pending.

The draft BUA letter was shown.

A member made a motion to approve the draft BUA letter for Dr. Koelle. Another member seconded the motion.

The Committee voted to approve the draft BUA for Dr. Koelle pending completion of an occupational health review and lab inspection responses, with one member abstaining.

---

y. Shah, Javeed A, renewal, *Immunology and Genetics of Infectious Diseases and Vaccines*

Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.

The Shah lab aims at understanding why individuals have different susceptibility to infections and whether these insights can lead to novel treatment and vaccine strategies.

This lab works with *Mycobacterium tuberculosis* at BSL-3.

A lab inspection has been performed and is still pending a response.
• All required trainings are complete.
• The project has an IACUC protocol in review.
• The draft BUA letter was shown.
• A member made a motion to approve the draft BUA letter for Dr. Shah. Another member seconded the motion.
• The Committee voted unanimously to approve the draft BUA for Dr. Shah pending completion of the IACUC revisions.

z. Specht, Jennifer, new, A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid-Tumor Malignancies

- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is a clinical study to evaluate the safety and tolerability of LYL797 in patients with relapsed/refractory TNBC and NSCLC and determine the recommended Phase 2 dose (RP2D) of LYL797. Additionally, they aim to evaluate the anti-tumor activity of LYL797 and the pharmacokinetics (PK) (e.g., expansion and persistence) in peripheral blood (PB) samples of LYL797.
- All required trainings are complete.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Specht. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Specht.

10. FOR YOUR INFORMATION:

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS: There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 12:05 P.M.